In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Stemline Therapeutics Inc (STML), with a price target of $35. The company’s shares closed yesterday at $10.22.
Selvaraju commented:
“Our 12-month price target is derived from a discounted cash flow based asset value of $1.46B for 15% discount rate and 2% terminal growth rate. The company has approximately 42M shares outstanding after the recent financing. Probabilities of market entry ascribed to SL-401 and SL-701 are 100% and 45%, respectively.”
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -15.7% and a 24.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Stemline Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $30.17.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.55 and a one-year low of $7.82. Currently, Stemline Therapeutics Inc has an average volume of 593.6K.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.
Read More on STML:
